JNCE News and Press, Jounce Therapeutics Inc. From 10/27/22

CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results...

- Two preclinical posters highlighting the JTX-1484 program and LILRB family at SITC 2022 - - Two clinical posters highlighting data from the SELECT and INNATE trials at ESMO-IO - CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE),...

CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate in the followi...

Cambridge, Massachusetts-based Jounce Therapeutics, Inc. ( NASDAQ: JNCE ) lost ~29% in the pre-market trading Tuesday after the company announced that its experimental lung cancer therapy vopratelimab and pimivalimab combo failed to reach primary endpoint in a mid-stage stud...

- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks - - Encouraging trends in improved mean tumor change over 9 and 18 weeks, and secondary endpoints o...

Jounce Therapeutics, Inc. (JNCE) Q2 2022 Earnings Conference Call August 04, 2022 08:00 AM ET Company Participants Eric Laub - Vice President-Investor Relations Richard Murray - Chief Executive Officer & President Beth Trehu - Chief Medical Officer Dmitri...

Jounce Therapeutics press release ( NASDAQ: JNCE ): Q2 GAAP EPS of -$0.65 beats by $0.04 . For further details see: Jounce Therapeutics GAAP EPS of -$0.65 beats by $0.04

- INNATE trial of JTX-8064 +/- pimivalimab on track to present preliminary data on at least 80 Phase 2 patients across multiple cohorts by year end - - Patient enrollment complete in the randomized, Phase 2 SELECT trial of vopratelimab in combination with pimivalimab; Data to be...

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report second quarter 2022 financial result...

Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...